V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Revvity Executive Compensation (FY25)

RVTY · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): May 1, 2026
404 figures on this page: 393 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Prahlad R. Singh
Latest say-on-pay support
=
April 28, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Prahlad R. Singh: $11,926,615 → $13,809,549 (15.8% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Revvity's chief executive and what were they paid?
Total compensation for Prahlad R. Singh, President and Chief Executive Officer, came to $13,809,549 in fiscal 2025. Compared with the $11,926,615 reported for fiscal 2024, Singh's total was 15.8% higher.
What was Revvity's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 96.2% of votes cast for or against in favor at the meeting held April 28, 2026.
Which companies are in Revvity's peer group?
Companies named in the disclosed peer group include Agilent Technologies, Inc., Avantor, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation and Bruker Corporation, among others.
What is Revvity's chief executive pay ratio?
The company reported a chief executive pay ratio of 239:1 for fiscal 2025, against median employee compensation of $57,745.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Prahlad R. Singh
President and Chief Executive Officer
◇—◇◇◇—◇◇
Maxwell Krakowiak
Senior Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Joel S. Goldberg
Senior Vice President, Administration, General Counsel and Secretary
◇—◇◇◇—◇◇
Tajinder S. Vohra
Senior Vice President, Global Operations
◇—◇◇◇—◇◇
Miriame Victor
Senior Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Prahlad Singh
Chief Executive Officer
◇—◇◇◇—◇◇
Joel Goldberg
Senior Vice President, Administration, General Counsel and Secretary
◇—◇◇◇—◇◇
Maxwell Krakowiak
Senior Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Miriame Victor
Senior Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Tajinder Vohra
Senior Vice President, Global Operations
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Prahlad R. Singh
President and Chief Executive Officer
◇—◇◇◇—◇◇
Maxwell Krakowiak
Senior Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Miriame Victor
Senior Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Joel S. Goldberg
Senior Vice President, Administration, General Counsel and Secretary
◇—◇◇◇—◇◇
Tajinder S. Vohra
Senior Vice President, Global Operations
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Joel S. GoldbergRSU◇——◇——◇
Joel S. GoldbergOPTION◇——◇—◇◇
Joel S. GoldbergPSU◇◇◇—◇—◇
Maxwell KrakowiakOPTION◇——◇—◇◇
Maxwell KrakowiakOPTION◇——◇—◇◇
Maxwell KrakowiakPSU◇◇◇—◇—◇
Maxwell KrakowiakRSU◇——◇——◇
Miriame VictorOPTION◇——◇—◇◇
Miriame VictorOPTION◇——◇—◇◇
Miriame VictorPSU◇◇◇—◇—◇
Miriame VictorRSU◇——◇——◇
Prahlad R. SinghOPTION◇——◇—◇◇
Prahlad R. SinghRSU◇——◇——◇
Prahlad R. SinghPSU◇◇◇—◇—◇
Tajinder S. VohraPSU◇◇◇—◇—◇
Tajinder S. VohraRSU◇——◇——◇
Tajinder S. VohraOPTION◇——◇—◇◇
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Tajinder VohraOption◇—◇—
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
Maxwell KrakowiakOption◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
PSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Miriame VictorOption◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Prahlad SinghPSU◇◇——
Option◇—◇—
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Joel GoldbergRSU◇◇——
Option◇—◇—
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇—
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Alexis P. Michas
Board chair
◇◇———◇◇
Samuel R. Chapin
◇◇————◇
Peter Barrett, PhD
◇◇————◇
Michel Vounatsos
◇◇————◇
Sophie V. Vandebroek, PhD
◇◇———◇◇
Frank R. Witney, PhD
◇◇———◇◇
Pascale Witz
◇◇————◇
Michael A. Klobuchar
◇◇————◇
Michelle McMurry-Heath, MD, PhD
◇◇————◇
Prahlad R. Singh, PhD served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Agilent Technologies, Inc. A
  • Avantor, Inc. AVTR
  • Bio-Rad Laboratories, Inc. BIO
  • Bio-Techne Corporation TECH
  • Bruker Corporation BRKR
  • Catalent, Inc. CTLT
  • Danaher Corporation DHR
  • Exact Sciences Corporation EXAS
  • Hologic, Inc. HOLX
  • Illumina, Inc. ILMN
  • QIAGEN N.V. QGEN
  • QuidelOrtho Corporation QDEL
  • The Cooper Companies, Inc. COO
  • Thermo Fisher Scientific Inc. TMO
  • Waters Corporation WAT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 28, 2026=◇◇◇
2024April 22, 2025=◇◇◇
2023April 23, 2024=◇◇◇
2022April 25, 2023=◇◇◇
2021April 26, 2022=◇◇◇
2020April 27, 2021=◇◇◇
2019April 28, 2020=◇◇◇
2018April 23, 2019=◇◇◇
2017April 24, 2018=◇◇◇
2016April 25, 2017=◇◇◇
2015April 26, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Revvity files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Revvity disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Revvity sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Revvity's disclosed peer group is defensible, who names Revvity back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
404 figures on this page: 393 cited to the filing that reported them, 11 calculated from figures it prints.
393 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001193125-26-201401
  2. 0001193125-26-107266
    2025 Director Compensation · 2025 Grants of Plan-Based Awards · CEO Pay Ratio · DIRECTOR COMPENSATION · and 2 more sections
  3. 0001193125-25-096747
  4. 0001193125-25-052522
    Summary Compensation Table
  5. 0001193125-24-110060
  6. 0001193125-24-066406
    Summary Compensation Table
  7. 0001193125-23-126948
  8. 0001193125-22-133586
  9. 0001193125-21-144984
  10. 0001193125-20-130958
  11. 0001193125-19-117178
  12. 0001193125-18-131329
  13. 0001193125-17-148115
  14. 0001193125-16-559458
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Revvity executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/RVTY (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Revvity and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Revvity discloses

The companies named in RVTY's own disclosed peer group.

Agilent Technologies, Inc.Avantor, Inc.Bio-Rad Laboratories, Inc.Bio-Techne CorporationBruker CorporationHologic, Inc.Illumina, Inc.The Cooper Companies, Inc.Waters Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy